Reportlinker Adds Global Protein Drugs Industry
NEW YORK, Sept. 30 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0305169/Global-Protein-Drugs-Industry.html
This report analyzes the Global market for Protein Drugs in US$ Million by the following Drug Classes - Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Others (Including Peptide Antibiotics and Enzymes). Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 56 companies including many key and niche players such as Abbott Laboratories, Inc., Alexion Pharmaceuticals, Inc., Amgen, Inc., Biogen Idec, Bristol-Myers Squibb Company, Medarex, Inc., Crucell N.V., Dendreon Corporation, Eli Lilly and Company, Emergent BioSolutions, Inc., Genentech, Inc., Johnson & Johnson, Centocor Ortho Biotech, Inc., MedImmune, Inc., Merck Serono S.A., Schering-Plough Corporation, UCB Group, Unigene Laboratories, Inc., and Vaccinogen, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
PROTEIN DRUGS MCP-6377
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
A Prelude II-1
Protein Drugs Are the Best Sellers II-1
Key Statistics: II-2
Table 1: World Market for Biopharmaceuticals (2009): Top 10
Brands Ranked by Dollar Sales (In US$ Billion) (includes
corresponding Graph/Chart) II-2
Table 2: World Market for Biopharmaceuticals (2007 & 2008):
Top 15 Brands Ranked by Dollar Sales (In US$ Billion) II-2
Competitive Scenario II-3
Intensifying Consolidation Activity II-3
Impact of Recession: A Review II-3
Impact of Recession on Drug Sales II-3
Impact of Recession on R&D Activities II-4
Not Recession, But Generic Competition Will Cause Sales Erosion II-4
Patent Expiration II-4
Impending Patent Expiry For Key Protein Drugs II-5
Patent Expirations For Key Protein and Peptide Drugs in the
Recent Past II-5
Follow-on Biologics: An Opportunity in Adverse Conditions II-6
Legal and Scientific Viability of Follow-on Protein Drugs II-6
MAb: A Market Better Protected from Generic Competition II-6
Approved Monoclonal Antibodies in the Market II-7
Unmet Medical Needs in Emerging Markets Provides Fertile
Environment II-7
Key Market Trends & Issues: A Review II-8
Continuous Fight Against Diseases: A Key Propeller for Growth II-8
Population Aging Makes Rise Of Protein Drugs Inevitable II-8
Ability to Address Wide Gamut of Diseases is Key to Success II-8
Combination Biologics Can Offer New Treatment Possibilities II-9
Shift Towards Humanized and Fully Human Antibodies II-9
Biotechnology Gives a New Direction II-9
Innovative Drug Delivery Methods: The Need of the Hour II-10
Companies Seek Partnerships and Collaborations to Sustain
Profit Margins II-10
Increasing Demand for Protein A in Mab Manufacturing II-11
Rising Number of MAbs Under Clinical Trials II-11
Major Protein Drugs in Pipeline As of 2009 II-11
Untapped Pharmacological Potential of GPCRs Ignites Interest II-12
Increased Reliance On Contract Manufacturing II-14
Reimbursement & Price Sensitivity Are Key Challenges II-14
Manufacturing Bottleneck II-15
High Costs Impede Penetration II-15
A Special Focus On Key Regional Markets II-15
United States II-15
Market Overview II-15
Biologicals: A Review II-15
Biologicals: A Costly Preposition II-16
Recombinant Proteins To Continue Their Significance as
Key Biologic Products II-16
Recombinant Blood-Related Agents to Continue Their
Market Growth II-16
Early Generic Competition Will Unsettle Revenues for Key
Protein Drugs II-16
Key Statistics: II-17
Table 3: US Market for Protein Therapeutics (2010):
Percentage Share Breakdown of Dollar Sales for Key Therapy
Area (includes corresponding Graph/Chart) II-17
China II-18
Market Overview II-18
China to Emerge As Biosimilar Major II-18
Lack of Regulatory Framework II-18
India II-18
Market Overview II-18
Indian Pharma Companies Gear Up to Grab a Big Slice of
Global Follow-On Biologics Market II-19
Openness in US Market Will Provide Opportunities II-19
2. PRODUCT OVERVIEW II-20
An Introduction II-20
Structural Information II-20
Classification of Proteins II-21
Sources of Protein Drugs II-21
Types of Protein-Based Drugs II-21
Cytokines II-21
Clotting factors II-22
Hormones II-22
Monoclonal Antibodies (Mabs) II-22
Vaccines II-22
Different Types of Protein Drugs II-22
Applications II-23
Significance of Biotechnology in Protein-Based Drugs II-23
Hybridoma Cell Technology II-23
Recombinant DNA Technology II-23
Production of Protein Drugs through Transgenic Animals II-23
Disadvantages of Protein-based Drugs II-24
Immunogenicity of Protein-Based Drugs II-24
3. PRODUCT INTRODUCTIONS/LAUNCHES II-25
Millipore Launches Magna RIPTM RNA-binding
ProteinImmunoprecipitation Kit II-25
Millipore Unveils AllostericProfilerTM Service II-25
Caliper Life Sciences Introduces Two Products to Expand
LabChip GX Product Range II-25
BioDtech Introduces EndoPrep II-26
Amgen Introduces Vectibix II-26
Trevigen Introduces Mouse Monoclonal Antibody II-26
UCB Receives FDA Approval for Cimzia® II-27
MD Biosciences Launches Keratocan and Lumican Monoclonal
Antibodies II-27
PhyNexus Introduces PhyTip® ProPlus™ Columns II-27
4. RECENT INDUSTRY ACTIVITY II-28
Novartis Vaccines Receives EC Approval for Menveo® II-28
Lonza Takes Over Algonomics II-28
Daicel Chemical Takes Over ChromTech II-29
Roche Licenses ProTek Stabilisation Technology of Aegis
Therapeutics II-29
Lonza to Manufacture Arzerra II-29
Sanofi Pasteur Receives FDA Approval for Fluzone® High-Dose
Vaccine II-29
Maxygen and Astellas Complete Joint Venture Transaction II-30
Sanofi Pasteur's Panenza® and Humenza® Vaccines Elicit Strong
Immune Response II-30
Amgen Collaborates with GSK II-30
Nabi Biopharmaceuticals Inks Licensing Agreement with GSK II-30
Wyeth Pharmaceuticals and Ambrx Enter into Strategic Alliance II-31
OPKO Health and Academia Sinica Ink Exclusive License Agreement II-31
Seattle Life Sciences and ZymoGenetics Enter into Licensing Pact II-32
Roche and Covagen Enter into Collaboration II-32
Lonza to Manufacture Biologics for LFB and Medarex II-32
Protgen Establishes Protein Drug Innovation Center in Beijing II-32
National Cheng Kung University Inks MoU with ScinoPharm Taiwan II-32
Novo Nordisk and ZymoGenetics Signs Licensing Agreement II-33
Lipoxen Signs Collaboration Agreement with Pharmasynthez II-33
Debiopharm Group Inks License Agreement with Curis II-33
Bristol-Myers Squibb Acquires Medarex II-34
Sanofi Pasteur Signs Licensing Agreement with Syntiron II-34
Sanofi Pasteur Inks Strategic Agreement with ShanH II-34
Access Pharmaceuticals Acquires Somanta Pharmaceuticals II-34
IMUC Completes Molecular Antibody Technology Acquisition II-35
Callisto Merger Corporation Merges with Celldex Therapeutics II-35
Arana and Kyowa Hakko Sign Agreement to Jointly Develop ART 104 II-35
Eusa Sells Antibody Research Business II-36
Dyax and Sanofi-Aventis Sign Agreements II-36
HGS Enters into Antibody Collaboration Agreement with Xencor II-37
Wyeth Pharmaceuticals and Biovitrum Extend ReFacto Supply
Agreement II-37
Caprotec Bioanalytics and Merck Ink Collaboration Agreement II-37
Biomonitor Snaps Up Neutekbio II-38
GE Healthcare Takes Over MicroCal II-38
Arana Therapeutics Enters into Collaboration with Greenovation
Biotech II-38
Bayer Healthcare Acquires Hemophilia Program Assets of Maxygen II-39
Sanofi Pasteur Holding Purchases Acambis II-39
GlaxoSmithKline Enters into Strategic Alliance with Archemix II-39
Talecris Biotherapeutics Inks License Agreement with Crucell II-40
Polyphor Signs Exclusive Licensing Agreement with Allergan II-40
Morphotek® Enters into Partnership with Pivotal BioSciences II-40
PharmAthene Snaps Up Biodefence Vaccines Business of Avercia
Biologics II-40
Raven Biotechnologies and CMC ICOS Biologics Ink an Agreement II-41
MacroGenics Purchases Raven Biotechnologies II-41
5. FOCUS ON SELECT PLAYERS II-42
Abbott Laboratories, Inc. (US) II-42
Alexion Pharmaceuticals, Inc. (US) II-42
Amgen, Inc. (US) II-42
Biogen Idec (US) II-43
Bristol-Myers Squibb Company (US) II-43
Medarex, Inc. (US) II-44
Crucell N.V. (The Netherlands) II-44
Dendreon Corporation (US) II-44
Eli Lilly and Company (US) II-44
Emergent BioSolutions, Inc. (US) II-45
Genentech, Inc. (US) II-45
Johnson & Johnson (US) II-46
Centocor Ortho Biotech, Inc. (US) II-46
MedImmune, Inc. (US) II-46
Merck Serono S.A. (Switzerland) II-47
Schering-Plough Corporation (US) II-47
UCB Group (Belgium) II-47
Unigene Laboratories, Inc. (US) II-48
Vaccinogen, Inc. (US) II-48
6. GLOBAL MARKET PERSPECTIVE II-49
Table 4: World Recent Past, Current & Future Analysis for
Protein Drugs by Geographic Region - US and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) II-49
Table 5: World 10-Year Perspective for Protein Drugs by
Geographic Region - Percentage Breakdown of Dollar Sales for
US and Rest of World Markets for Years 2006, 2009, and 2015 II-49
Table 6: World Recent Past, Current and Future Analysis for
Protein Drugs by Drug Type - Antibodies, Blood Products,
Cytokines, Peptide Hormones, Vaccines, and Other Drugs
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) II-50
Table 7: World 10-Year Perspective for Protein Drugs by Drug
Type - Percentage Breakdown of Dollar Sales for Antibodies,
Blood Products, Cytokines, Peptide Hormones, Vaccines, and
Other Drugs for Years 2006, 2009, and 2015 (includes
corresponding Graph/Chart) II-51
III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 56 (including Divisions/Subsidiaries - 58)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 34
Canada 2
Japan 1
Europe 18
France 1
Germany 3
The United Kingdom 4
Rest of Europe 10
Asia-Pacific (Excluding Japan) 3
------------------------------------------
To order this report:
Drug and Medication Industry: Global Protein Drugs Industry
Drug and Medication Business News
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article